Joao Monteiro, Chief Editor at Nature Medicine, shared a post on LinkedIn:
“In our latest editorial in Nature Medicine, we call for innovative strategies to record and manage the toxicity and long-term effects of the new generation of anti-cancer drugs.
Recent breakthroughs in cancer therapy, including immunotherapies, antibody–drug conjugates, bispecific antibodies, and have transformed oncology care. Just two months ago, researchers found that the pan-RAS inhibitor daraxonrasib doubled the survival of patients with aggressive RAS oncogene-driven advanced pancreatic cancer, which had thus far had very limited treatment options.
These new treatments bring with them a range of adverse effects, some of which are acute and clinically-manageable. Their long-term impact on the quality of life of those who survive cancer is unclear.
As this new generation of cancer drugs – and hopefully many more to come – continues to extend the lives of people with cancer, it is paramount that strategies for recording and managing their toxicity and long-term effects evolve at a fast pace.”
Title: Oncology must confront hidden side effects
Read the Full Editorial on Nature Medicine
Other posts featuring Joao Monteiro on OncoDaily.